<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01408069</url>
  </required_header>
  <id_info>
    <org_study_id>ACHEMS0211</org_study_id>
    <nct_id>NCT01408069</nct_id>
  </id_info>
  <brief_title>Non-Inferiority Comparison of Migrane速 Versus Parcel 速 For Treatment of Tensional Cephaleia</brief_title>
  <official_title>Multicentric, Randomizade, Double Blind, Double Dummy To Non-Inferiority Comparison Of Migrane速 Versus Parcel 速 For Treatment Of Tensional Cephaleia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the non-inferiority clinical efficacy of two
      different associations of drugs in the treatment of patients diagnosed with tensional-type
      headache in accordance with International Headache Society guidelines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Open-label, non-inferiority, prospective, parallel group, intent to treat trial.

        -  Experiment duration: 56 days.

        -  04 visits (days -7, 0, 28 and 56).

        -  Efficacy will be evaluated for 10 episodes of tension-type headache.

        -  Adverse events evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study suspended by decision strategically.
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of treatment in relieve headache symptoms.</measure>
    <time_frame>1 hour</time_frame>
    <description>The evaluation of efficacy will be determined based on comparison of the intensity of headache before and after 30, 60 and 90 minutes of initiation of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of study treatment</measure>
    <time_frame>56 days</time_frame>
    <description>Tolerability will be assessed by the investigator through the number of adverse events definitely related to study medication. This relationship will be defined by applying the Naranjo algorithm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Tensional-type Headache</condition>
  <arm_group>
    <arm_group_label>MIGRANE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 to 2 tablets ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PARCEL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MIGRANE</intervention_name>
    <description>1 to 2 tablets(ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg)</description>
    <arm_group_label>MIGRANE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PARCEL</intervention_name>
    <description>1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)</description>
    <arm_group_label>PARCEL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must be able to understand the study procedures agree to participate and give
             written consent.

          2. Tensional-type headache patients according to the International Headache Society
             criteria.

          3. Corporal body indices &lt; 40.

        Exclusion Criteria:

          1. Pregnancy or risk of pregnancy.

          2. Lactation

          3. Use of acetylsalicylic acid or corticosteroids or immunosuppressive therapy.

          4. Use of immunosuppressive drugs.

          5. Alterations of laboratory selective tests.

          6. Drugs or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2011</study_first_submitted>
  <study_first_submitted_qc>August 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2011</study_first_posted>
  <last_update_submitted>March 25, 2013</last_update_submitted>
  <last_update_submitted_qc>March 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>headache</keyword>
  <keyword>migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Ergotamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

